Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Redhill Biopharma Ltd RDHL

Healthcare
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204... see more

Recent & Breaking News (NDAQ:RDHL)

RedHill Extends Talicia Commercial Coverage

Accesswire July 20, 2021

RedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia® with OptumRx

PR Newswire July 20, 2021

RedHill Biopharma Ltd Announces RedHill Biopharma Announces Last Patient Out

Accesswire July 19, 2021

RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib

PR Newswire July 19, 2021

RedHill Biopharma's Movantik® Added as Unrestricted Preferred Brand To A Major National Commercial Formulary Serving over 30 Million Americans

PR Newswire July 13, 2021

RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study

PR Newswire June 28, 2021

RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19

PR Newswire June 21, 2021

RedHill Biopharma to Present at the BIO Digital International Convention

PR Newswire June 9, 2021

RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study

PR Newswire June 7, 2021

35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021

Accesswire May 27, 2021

RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights

PR Newswire May 27, 2021

RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19

PR Newswire May 26, 2021

RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021

PR Newswire May 24, 2021

RedHill Biopharma Presents a New Travelers' Diarrhea Clinical Severity Classification Tool and its Use in Aemcolo Efficacy Analysis at DDW 2021

PR Newswire May 21, 2021

RedHill Biopharma to Host First Quarter 2021 Financial Results and Operational Highlights Webcast on May 27, 2021

PR Newswire May 20, 2021

RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue

PR Newswire April 9, 2021

RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSN Pharmaceuticals

PR Newswire March 25, 2021

RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland

PR Newswire March 22, 2021

RedHill Biopharma Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

PR Newswire March 18, 2021

RedHill Biopharma to Host Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Webcast on March 18, 2021

PR Newswire March 11, 2021